Call Us Today:
949.200.1600

Bowen's Disease

Home >Diagnosis > Squamous Cell Carcinoma > Bowen's Disease

Bowens-Disease-Skin-Cancer-Specialists-Skin-Cancer-and-Reconstructive-Surgery-Center-Orange-County

About Bowen's Disease

Bowen’s disease or squamous cell carcinoma in situ is a cutaneous neoplasm with a 3-5% risk of invasive carcinoma. It is of particular interest due to the plethora of treatment modalities available. Sun exposure is one of the causes of Bowen’s carcinoma, but over ½ of cases have detectable oncogenic HPV types 16 and 18. The implication is that HPV-induced Bowen’s disease should be responsive to agents with antitumor and antiviral effect. Most therapeutic options for Bowen’s disease, except Mohs excision, have failure and recurrence rate of 10%-20%, and no treatment modality is best in all clinical scenarios.

About Bowen's Disease

5-fluorouracil (5-FU) is usually applied once or twice daily as a 5% cream for up to 2 months and can be repeated if needed. The median clearance rate with 5-FU among the studies is 80-90% with 10-20% recurrence rate. Although some show better and some worse results, the variability of treatment regimens and study design account for part of that. 5-FU can be an irritant affecting patient compliance. To limit irritation of treatment, less aggressive regimens have been employed with diminished clearance rates and long term control rates. In those cases additional cycles of treatment are needed to improve clearance and limit recurrence.

 

Imiquimod (Aldara) has the unique role as both an anti-tumor agent and an anti-viral agent given its immunomodulating action. This fits the large portion of Bowen’s disease, having an HPV association. Imiquimod applied daily for 16 weeks produced a cure rate between 73% and 93% in several studies. Like 5-FU, some imiquimod patients have significant skin reactions to treatment. These can be severe enough to stop the treatment prematurely.

 

An innovative approach obtained 100% cure rate utilizing cryoimmunotherapy in a single study. Liquid nitrogen cryospray was applied one week prior to a 6-week course of 5% imiquimod applied 5 of 7 days. A few patients required application of tretinoin 0.025% cream to incite a reaction by enhancing imiquimod penetration. The theory is that liquid nitrogen damages the integrity of the stratum corneum thereby facilitating cream penetration.¹

 

Cryotherapy alone also has a failure rate of up to 30%. However, success rate up to 90% at 12 months has been shown, provided that an adequate freeze-thaw cycle is applied. Examples of freeze-thaw cycles (FTC) are a single 30 second FTC, two 20 second FTC with a thaw period, or up to three single treatments of 20 seconds at intervals of several weeks. Although effective for smaller lesions, treatment of broad lesions or lower leg lesions may be impractical due to discomfort and slow healing. Curettage and cautery (electrodessication and curettage, ED&C) may be preferable to cryotherapy in terms of pain, healing, and recurrence rate (up to 20% with ED&C).

 

Photodynamic therapy (PDT) is also successful with Bowen’s disease by the virtue of being able to treat large areas. Despite the reports of superior cosmesis and healing, PDT can have associated erythema, edema, and pain. It requires one, two, or more treatments with a clearance rate of up to 90% and recurrence rate of 10-20% or higher.

 

Various radiotherapy techniques have been used to treat Bowen’s disease. Response of up to 100% has been documented with recurrence rates of 0-10%. Limitations of radiotherapy has been non-healing on the lower leg of up to 20%. However, in those studies, larger energies have been utilized (100 and 120 kVa). This compares to current recommendations of 50-80 kVA of superficial radiotherapy where such complications can be avoided.

 

Finally, Mohs surgery remains the gold standard for treatment of Bowen’s disease except for small trunk and extremity lesions. It had a 6-8% recurrence rate. It is particularly effective for previously treated and recurrent Bowen’s disease.

 

Topical and destructive therapies have the potential to partially clear the lesion creating noncontiguous ‘‘skip’’ tumors. Aggressive surgical treatment would be required to achieve cure then. There is an additional risk to non-surgical treatments that must be considered – areas of invasive carcinoma within squamous cell carcinoma in situ. Additional sampling biopsies can help with that assessment, but ultimately clinical suspicion should guide the management.

Related Articles

Skin-Cancer-And-Reconstructive-Surgery-Foundation-Forehead-SCC-with-perineural-invasion-Beam’s-eye-view
Forehead SCC with Perineural Invasion
HISTORY   83-year-old man presented in 02/2017 with a 3-year history of a forehead and temple SCC. The cancer was initially treated with cryoablation and 5-FU. Excision on 9/2/16 was performed with residual circumferential margins. Histology found poorly differentiated sclerosing squamous cell carcinoma, with perineural invasion of 0.1 mm nerves.  Wide local resection with radial…
Read More
Skin-Cancer-And-Reconstructive-Surgery-Foundation-Scalp-SCC-Metastasis-to-neck-CT-PET-scan
Scalp SCC Metastasis to Neck
HISTORY   64-year-old man presents in 11/2017 with tender, right postauricular swelling. Fine needle aspiration biopsy showed squamous cell carcinoma. Extensive squamous cell carcinoma of scalp was treated with 4 levels of Mohs earlier that year in 01/2017. Additional smaller squamous cell carcinoma of the same area of the scalp was treated with Mohs in…
Read More
Deeply-Invasive-Squamous-Cell-Carcinoma-of-Cheek-Skin-Cancer-And-Reconstructive-Surgery-Foundation-Skin-Cancer-Conference-August-2017
Deeply Invasive Squamous Cell Carcinoma of Cheek
  HISTORY: 82-year-old man with a 1 year history of squamous cell carcinoma on the right lower cheek biopsied on 4/28/2017. Radical resection of the right cheek carcinoma and deep facial lymph node biopsy was performed. Intraoperative Mohs margin evaluation confirmed clear margins. Final permanent histology margins were close but clear. Evidence of perineural invasion…
Read More
SCARS-Center-Metastatic-Squamous-Cell-Carcinoma-Skin-cancer-jaw
Metastatic Squamous Cell Carcinoma
HISTORY 76-year-old man with a rapidly growing mass on angle of jaw. Fine needle aspiration on 12/6/16 diagnosed squamous cell carcinoma. The presumptive primary carcinoma was skin. On 12/16/16, the patient underwent a left parotidectomy and cervical lymphadenectomy. Pathology showed multiple lymph node involvement. Radiation and concurrent chemotherapy treatment began on 1/18/2017 and was completed…
Read More
SCARS-Center-Metastatic-Squamous-Cell-Carcinoma-of-Scalp-skin-cancer-scalp-2
Calvarial Invasion of scalp SCC
HISTORY 72-year-old man presents with an ulcerating skin lesion on the right scalp. In March 2013, a biopsy showed pleomorphic sarcoma and the histologic differential diagnosis included atypical fibroxanthoma and malignant fibrous histiocytoma. In May 2013, Mohs excision and additional resection of the outer table of the calvarium was completed. In April 2016, a new…
Read More
SCARS-Center-Aggressive-Forehead-SCC-Skin-Cancer-Forehead
Aggressive Forehead SCC
History 78-year-old man with a recurrence of squamous cell carcinoma of forehead following surgery and radiation. Resection was performed in 4/2016 and radiation followed. Lesion recurred within 1 week of completion of radiation within radiation field. Originally presented with squamous cell carcinoma with perineural invasion and 4.5mm depth of invasion, arising from squamous cell carcinoma…
Read More

STAY UP TO DATE

Receive research updates, inspiring stories, healthy living tips and more.

Something went wrong. Please check your entries and try again.

FOLLOW US

ELEVATING THE STANDARDS OF SKIN CANCER MANAGEMENT.

© 2018 SCARS Management Services. All rights reserved.